$99.1 Million is the total value of DAFNA Capital Management LLC's 59 reported holdings in Q3 2014. The portfolio turnover from Q2 2014 to Q3 2014 was 42.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PCYC | Sell | PHARMACYCLICS INC | $13,026,000 | +25.6% | 110,928 | -4.1% | 13.14% | +33.6% |
| STXS | Sell | STEREOTAXIS INC | $3,190,000 | -35.0% | 1,374,975 | -0.5% | 3.22% | -30.8% |
| BSTC | Sell | BIOSPECIFICS TECHNOLOGIES | $2,120,000 | +12.2% | 60,054 | -14.3% | 2.14% | +19.4% |
| GLMD | Sell | GALMED PHARMACEUTICALS LTD | $1,006,000 | -49.9% | 116,987 | -43.2% | 1.02% | -46.6% |
| AMPE | Sell | AMPIO PHARMACEUTICALS INC | $530,000 | -95.5% | 150,000 | -89.3% | 0.54% | -95.2% |
| RTIX | Sell | RTI SURGICAL INC | $411,000 | -43.5% | 85,918 | -48.6% | 0.42% | -39.8% |
| LPTN | Sell | LPATH INC | $362,000 | -13.2% | 102,798 | -2.1% | 0.36% | -7.6% |
| NSPR | Sell | INSPIREMD INC | $140,000 | -43.5% | 63,700 | -24.4% | 0.14% | -40.0% |
| NWBO | Exit | NORTHWEST BIOTHERAPEUTICS IN | $0 | – | -12,017 | -100.0% | -0.08% | – |
| RGDO | Exit | REGADO BIOSCIENCES INC | $0 | – | -30,000 | -100.0% | -0.19% | – |
| ARDX | Exit | ARDELYX INC | $0 | – | -25,000 | -100.0% | -0.38% | – |
| KERX | Exit | KERYX BIOPHARMACEUTICALS | $0 | – | -92,400 | -100.0% | -1.35% | – |
| ADHD | Exit | ALCOBRA LTD | $0 | – | -84,996 | -100.0% | -1.39% | – |
| BOTA | Exit | BIOTA PHARMACEUTICALS INC | $0 | – | -729,781 | -100.0% | -1.97% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STEREOTAXIS INC | 42 | Q3 2023 | 27.6% |
| ATRICURE INC | 42 | Q3 2023 | 11.4% |
| MASIMO CORPORATION | 42 | Q3 2023 | 1.8% |
| ASCENDIS PHARMA A S SPONSORED | 34 | Q3 2023 | 4.5% |
| AERIE PHARMACEUTICALS INC | 33 | Q3 2022 | 4.2% |
| GALAPAGOS NV-SPON ADR | 33 | Q3 2023 | 3.8% |
| XENON PHARMACEUTICALS INC | 33 | Q3 2023 | 3.6% |
| NEUROCRINE BIOSCIENCES INC | 32 | Q3 2023 | 2.9% |
| JOHNSON AND JOHNSON | 32 | Q1 2021 | 1.2% |
| ISHARES TR NASDQ BIOTECH | 30 | Q3 2023 | 4.0% |
View DAFNA Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Stereotaxis, Inc. | March 08, 2018 | 13,680,554 | 23.4% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2018 | 983,000 | 2.9% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2017 | 1,133,583 | 5.4% |
| WINDTREE THERAPEUTICS INC /DE/ | February 14, 2017 | 208,333 | 2.4% |
| ANAVEX LIFE SCIENCES CORP.Sold out | February 16, 2016 | 0 | 0.0% |
| DISCOVERY LABORATORIES INC /DE/ | February 16, 2016 | 10,658,699 | 9.2% |
| PRECISION OPTICS CORPORATION, INC. | February 13, 2015 | 311,537 | 5.0% |
| TearLab Corp | February 14, 2013 | 939,239 | 3.2% |
| VIKING SYSTEMS INC | February 14, 2012 | 3,781,468 | 5.2% |
View DAFNA Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
View DAFNA Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.